[Behçet disease. Genetic factors, immunologic aspects and new therapeutic methods].
METHODS
The pathogenesis of Behcetp3disease is still unknown, although a genetic predisposition appears to play an important role with a strong association with the MICA gene located between the HLA-B and TNF genes rather than HLA B51. Abnormal immune responses affect especially cellular immunity and significant T-cell proliferative responses by the gamma ô subset of T cells are shown after stimulation with heat shock protein peptides. Systemic levels of the soluble TNF R-75 and IL 12 could be the best biological markers of disease activity.
Systemic colchicine being implicated in polynuclear neutrophil over-production of toxic super-oxides, its prescription for controlling eye involvement should be reevaluated. Steroids and immunosuppressive drugs are still the treatment of choice for severe manifestations of the disease. Beneficial effects of cyclosporine are established in uveitis. Tacrolimus (FK 506) and pentoxifylline may be valuable.
Service de Médecine interne, CHU Hôtel-Dieu de France, Beyrouth, Liban.
A
A
Tohme
I
I
el-Khoury
E
E
Ghayad
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents
La maladie de Behçet. Facteurs génétiques, aspects immunologiques et nouveautés thérapeutiques.